Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03943537 · ClinicalTrials.gov registry record · Phase 2

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

A Phase 2 study, sponsored by Mclean Hospital.

Completed
Registry status
Phase 2
Development phase
87
Enrollment target

NCT03943537: Completed Phase 2 study, sponsored by Mclean Hospital.

NCT03943537 is a Phase 2 study that has completed, run by Mclean Hospital. The registered enrollment target is 87 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03943537, a Phase 2 study, has completed, sponsored by Mclean Hospital.

COMPLETED
Registry status
Phase 2
Development phase
87 participants
Enrollment target

Study Summary

This clinical trial is a single center, single dose study of the acute effects of intranasal insulin on energy metabolism and cognitive function in patients with schizophrenia, schizoaffective and bipolar disorders, compared and healthy controls.

Primary Outcome

Changes in brain NAD+/NADH ratio as measured by in vivo 31P magnetic resonance spectroscopy

Interventions

  • DRUG Intranasal Insulin

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2019-10-01
Est. Completion 2024-02-23
Phase Phase 2
Mclean Hospital

140 total trials

What the finished NCT03943537 record still lists

NCT03943537 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).

The record links to 0 conditions, and to 1 intervention - of which Intranasal Insulin is the first listed.

NCT03943537 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03943537 about?

NCT03943537 is a clinical study titled "Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders". This clinical trial is a single center, single dose study of the acute effects of intranasal insulin on energy metabolism and cognitive function in patients with schizophrenia, schizoaffective and bipolar disorders, compared and healthy controls.

What is the current status of trial NCT03943537?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2019-10-01. Estimated completion is 2024-02-23.

What interventions are being tested in trial NCT03943537?

The interventions under investigation include: Intranasal Insulin (DRUG).

Who is sponsoring clinical trial NCT03943537?

This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03943537's enrollment target sits among peer trials

87 810th of 2000 higher than 1,189 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03292601 · 87 participants · NA

    Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)

  • NCT04291105 · 87 participants · Phase 2

    Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

  • NCT04565795 · 87 participants · NA

    Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

  • NCT05607004 · 87 participants · Phase 2

    (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03943537, the US trial registry maintained by the National Library of Medicine. NCT03943537 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.